Compound: Retatrutide Format: Lyophilized peptide research vial Available Strengths: 10MG, 20MG, and 30MG Research Category: GLP-1 / GIP / glucagon triple agonist peptide research Research Focus: Incretin biology, metabolic regulation, GLP-1 receptor pathway research, GIP receptor signaling, glucagon receptor models, substrate utilization, energy-balance biology, and appetite-associated pathway research
Novo Nordisk has the infrastructure, regulatory experience, and manufacturing capacity from commercializing the most successful GLP-1 agonist on the market
Plant-based antidiabetic nanoformulations: The emerging paradigm for effective therapy
Request Prescribing Access
- Enhance Energy Levels: The combination of ingredients can help boost energy and reduce fatigue